Angiotensin-converting enzyme 2 protects from severe acute lung failure
Yumiko Imai, Keiji Kuba, Shuan Rao, Yi Huan, Feng Guo, Bin Guan, Peng Yang, Renu Sarao, Teiji Wada, Howard Leong-Poi, Michael A Crackower, Akiyoshi Fukamizu, Chi-Chung Hui, Lutz Hein, Stefan Uhlig, Arthur S Slutsky, Chengyu Jiang, Josef M Penninger, Yumiko Imai, Keiji Kuba, Shuan Rao, Yi Huan, Feng Guo, Bin Guan, Peng Yang, Renu Sarao, Teiji Wada, Howard Leong-Poi, Michael A Crackower, Akiyoshi Fukamizu, Chi-Chung Hui, Lutz Hein, Stefan Uhlig, Arthur S Slutsky, Chengyu Jiang, Josef M Penninger
Abstract
Acute respiratory distress syndrome (ARDS), the most severe form of acute lung injury, is a devastating clinical syndrome with a high mortality rate (30-60%) (refs 1-3). Predisposing factors for ARDS are diverse and include sepsis, aspiration, pneumonias and infections with the severe acute respiratory syndrome (SARS) coronavirus. At present, there are no effective drugs for improving the clinical outcome of ARDS. Angiotensin-converting enzyme (ACE) and ACE2 are homologues with different key functions in the renin-angiotensin system. ACE cleaves angiotensin I to generate angiotensin II, whereas ACE2 inactivates angiotensin II and is a negative regulator of the system. ACE2 has also recently been identified as a potential SARS virus receptor and is expressed in lungs. Here we report that ACE2 and the angiotensin II type 2 receptor (AT2) protect mice from severe acute lung injury induced by acid aspiration or sepsis. However, other components of the renin-angiotensin system, including ACE, angiotensin II and the angiotensin II type 1a receptor (AT1a), promote disease pathogenesis, induce lung oedemas and impair lung function. We show that mice deficient for Ace show markedly improved disease, and also that recombinant ACE2 can protect mice from severe acute lung injury. Our data identify a critical function for ACE2 in acute lung injury, pointing to a possible therapy for a syndrome affecting millions of people worldwide every year.
Conflict of interest statement
J.M.P. declares personal financial interests.
Figures
References
- Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 1995;151:293–301. doi: 10.1164/ajrccm.151.2.7842182.
- Ware LB, Matthay MA. The acute respiratory distress syndrome. N. Engl. J. Med. 2000;342:1334–1349. doi: 10.1056/NEJM200005043421806.
- Vincent JL, Sakr Y, Ranieri VM. Epidemiology and outcome of acute respiratory failure in intensive care unit patients. Crit. Care Med. 2003;31(suppl.):S296–S299. doi: 10.1097/01.CCM.0000057906.89552.8F.
- Ksiazek TG, et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1953–1966. doi: 10.1056/NEJMoa030781.
- Drosten C, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1967–1976. doi: 10.1056/NEJMoa030747.
- Donoghue M, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ. Res. 2000;87:E1–E9. doi: 10.1161/01.RES.87.5.e1.
- Tipnis SR, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 2000;275:33238–33243. doi: 10.1074/jbc.M002615200.
- Crackower MA, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–828. doi: 10.1038/nature00786.
- Li W, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145.
- Hamming I, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203:631–637. doi: 10.1002/path.1570.
- Skeggs LT, Dorer FE, Levine M, Lentz KE, Kahn JR. The biochemistry of the renin-angiotensin system. Adv. Exp. Med. Biol. 1980;130:1–27. doi: 10.1007/978-1-4615-9173-3_1.
- Corvol P, Williams TA, Soubrier F. Peptidyl dipeptidase A: angiotensin I-converting enzyme. Methods Enzymol. 1995;248:283–305. doi: 10.1016/0076-6879(95)48020-X.
- Boehm M, Nabel EG. Angiotensin-converting enzyme 2—a new cardiac regulator. N. Engl. J. Med. 2002;347:1795–1797. doi: 10.1056/NEJMcibr022472.
- Tsang KW, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003;348:1977–1985. doi: 10.1056/NEJMoa030666.
- Lee N, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003;348:1986–1994. doi: 10.1056/NEJMoa030685.
- Poutanen SM, et al. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 2003;348:1995–2005. doi: 10.1056/NEJMoa030634.
- Tran TH, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 2004;350:1179–1188. doi: 10.1056/NEJMoa040419.
- Nagase T, et al. Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2. Nature Immunol. 2000;1:42–46. doi: 10.1038/76897.
- Imai Y, et al. Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. J. Am. Med. Assoc. 2003;289:2104–2112. doi: 10.1001/jama.289.16.2104.
- Martin EL, et al. Negative impact of tissue inhibitor of metalloproteinase-3 null mutation on lung structure and function in response to sepsis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003;285:L1222–L1232. doi: 10.1152/ajplung.00141.2003.
- Krege JH, et al. Male–female differences in fertility and blood pressure in ACE-deficient mice. Nature. 1995;375:146–148. doi: 10.1038/375146a0.
- Inagami T, et al. Cloning, expression and regulation of angiotensin II receptors. Adv. Exp. Med. Biol. 1995;377:311–317. doi: 10.1007/978-1-4899-0952-7_21.
- Gasc JM, Shanmugam S, Sibony M, Corvol P. Tissue-specific expression of type 1 angiotensin II receptor subtypes. An in situ hybridization study. Hypertension. 1994;24:531–537. doi: 10.1161/01.HYP.24.5.531.
- Sugaya T, et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem. 1995;270:18719–18722. doi: 10.1074/jbc.270.32.18719.
- Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature. 1995;377:744–747. doi: 10.1038/377744a0.
- Plante GE, Chakir M, Ettaouil K, Lehoux S, Sirois P. Consequences of alteration in capillary permeability. Can. J. Physiol. Pharmacol. 1996;74:824–833. doi: 10.1139/y96-090.
- Roy BJ, Pitts VH, Townsley MI. Pulmonary vascular response to angiotensin II in canine pacing-induced heart failure. Am. J. Physiol. 1996;271:H222–H227.
- Goggel R, et al. PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nature Med. 2004;10:155–160. doi: 10.1038/nm977.
- Hansen TN, Le Blanc AL, Gest AL. Hypoxia and angiotensin II infusion redistribute lung blood flow in lambs. J. Appl. Physiol. 1985;58:812–818. doi: 10.1152/jappl.1985.58.3.812.
- Marshall RP, et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 2002;166:646–650. doi: 10.1164/rccm.2108086.
Source: PubMed